Unlock instant, AI-driven research and patent intelligence for your innovation.

Methods for suppressing neovascularization using EphrinB2

A lumen, endothelial cell technology, applied in the field of angiogenesis and neovascularization, can solve problems such as unclear role

Inactive Publication Date: 2008-03-26
AQUMEN BIOPHARM
View PDF46 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the Eph receptor tyrosine kinase family represents a new class of RTKs, its role in angiogenesis remains unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for suppressing neovascularization using EphrinB2
  • Methods for suppressing neovascularization using EphrinB2
  • Methods for suppressing neovascularization using EphrinB2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0111] Evrin B2 inhibits growth factor-stimulated EC proliferation and migration

[0112] Treatment of human aortic epithelial cells (HAoEC) with VEGF, bFGF or PDGF-BB (10 ng / mL each) resulted in a 3-10 fold increase in DNA synthesis compared to untreated controls. Ephin B2 inhibited DNA synthesis stimulated by all these stimuli, whereas neither EphB4 nor Ephin B2+EphB4 inhibited. As shown in Figure 1A, the increase in DNA synthesis induced by 10 ng / mL VEGF, bFGF or PDGF-BB was inhibited by 40%, 30% and 90% by 200 μg / mL Evrin B2, respectively. Almost identical results were obtained using human umbilical vein endothelial cells (HUVEC) (Fig. 1B). No apparent apoptotic cells were observed during this incubation period (data not shown). At day 7, VEGF-induced lumen formation was reduced in the Evrin B2-treated group compared to the control group (Fig. 1C). In contrast, VEGF-induced lumen formation was not affected by EphB4 treatment.

[0113] Thus, evotin B2 is capable of inhi...

Embodiment 2

[0116] Effects of Evrin B2 on Growth Factor-Induced Phosphorylation of p42 / 44 ERK and Receptor Autophosphorylation

[0117] To investigate the mechanism by which evotin B2 inhibits VEGF- or bFGF-induced mitogenic responses on HAoECs, we examined the effect of evotin B2 on VEGF- or bFGF-stimulated ERK (p42 / 44) phosphorylation by Western analysis. Stimulation with 10 ng / mL VEGF or bFGF enhanced ERK phosphorylation. Evin B2 inhibits VEGF- and bFGF-induced ERK phosphorylation. For example, 200 μg / mL Evin B2 inhibited VEGF-induced ERK phosphorylation by 70% (Fig. 2A). We then investigated the autophosphorylation of VEGF-receptor 2 (KDR) in VEGF-stimulated HUVECs. 10 ng / mL VEGF increased VEGF-receptor 2 autophosphorylation by 14-fold. Evin B2 did not inhibit autophosphorylation of VEGF-receptor 2 (Fig. 2B). Essentially the same results were obtained with HUVECs (data not shown).

[0118] These results therefore indicate that evotin B2 inhibits VEGF- or bFGF-induced ERK phosphor...

Embodiment 3

[0120] Co-administration of Evrin B2 in mouse cornea inhibits bFGF-induced angiogenesis

[0121] bFGF is known to be a potent angiogenic factor. Since evotin B2 is able to inhibit bFGF-induced proliferation of EC cells, we examined whether evotin B2 is also capable of inhibiting angiogenesis.

[0122] We implanted Hydron pellets that had been infused with human bFGF into the corneas of mice. Six days after implantation, we examined the growth of new blood vessels. bFGF significantly induced angiogenesis in the mouse cornea. We further examined the effects of Ephrin B2 and EphB4 on bFGF-induced corneal neovascularization. Administration of ephrin B2 significantly blocked bFGF-induced angiogenesis, but administration of EphB4 showed no effect. Quantitative analysis also demonstrated that Evrin B2 completely inhibited bFGF-induced corneal neovascularization ( FIG. 3 ).

[0123] Thus, evotin B2 can be used to inhibit angiogenesis and neovascularization. In particular, these ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
Login to View More

Abstract

Methods for inhibiting DNA synthesis, MAP kinase activation, and tube formation of endothelial cells are provided. Also provided are methods for inhibiting angiogenesis and neovascularization, as well as compositions useful for the methods described herein.

Description

technical field [0001] The present invention relates to angiogenesis and neovascularization, and more particularly to the use of ephrin B2 therein. [0002] references [0003] Adams, R.H. et al. (2001), The cytoplasmic domain of the ligand ephrin B2 is required for vascular morphogenesis but not cranial neural crest migration crest migration), Cell 104(1):57-69. [0004] Adams, R.H. et al. (1999), Roles of ephrin B ligands and EphB receptors in cardiovascular development: arterial / venous domain demarcation, vascular morphogenesis, and sprouting angiogenesis (Roles of ephrinB ligands and EphB receptors in Cardiovascular development: demarcation of arterial / venous domains, vascular morphology, and sprouting angiogenesis), Genes Dev13(3):295-306. [0005] Gale, N.W. et al. (2001), Ephrin B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth muscle cells endothelial and smooth-muscle cells), Dev Biol 2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P27/00A61P5/32A61P35/00A61P19/02A61P43/00
CPCA61K38/19A61P3/10A61P5/32A61P9/00A61P9/10A61P15/00A61P19/02A61P27/00A61P27/02A61P29/00A61P35/00A61P43/00
Inventor 藤泽公彦石桥达朗畑快右键本忠尚
Owner AQUMEN BIOPHARM